

PET-CT Imaging Referral Form

Patient's Name		
Address	DOB	
	NHI#	
Email	Tel (hme)	
ACCIDENT YES NO ACC No.	Date of injury	
COVERED BY: ACC Accredited Employer	[name of employing company]	
MEDICAL INSURANCE? YES NO Provider		
DHB: DHB of Domicile DHB of Service		
Discussed at an MDM? MDM Name		
EXAMINATION REQUESTED		
· ·		
FDG NAF FET(brain) PSMA Other	Timing of scan	
Date results required If URGENT,	reason	
IMPORTANT SAFETY QUESTIONS - REFERRING CLINICIA	AN PLEASE COMPLETE	
Diabetic?	Outpatient Inpatient Ward	
Is your patient pregnant? Yes No Is	your patient infectious?	Yes No
Does your patient have allergies? Yes No	omment:	
Comment:In	terpreter needed?	Yes No
Renal Failure? Yes No Ap	prox. weight of patient	kg
eGFR/date(within 3 months)	prox. height of patient	cm
	DES YOUR PATIENT REQUIRE:	
	edation	Yes No
Does your patient have asthma? Yes No Ge	eneral Anaesthetic	∐Yes ∐No
IMPORTANT NOTES - FOR REFERRING CLINICIAN		
Ensure both sides of this form are completed and that it is signed by form to appointments@pacificradiology.com or fax to 04 978 5501.	the referring consultant, email the	completed
DHB FUNDED SCANS: Complete the form & give to your DHB Departm	nent Administrator.	
REFERRER DETAILS		
Name		
Address		<u>.</u>
Secretary Name Fax Fax	Phone	
Signature		
COPY TO:		
Name	Fax	
Address		
Name		

CEIMICAEAGDII	PLEASE FILL	IN OR TICK APPROPE	RIATE RESPONSES	FOR ALL CASES		
PRIMARY CONDITION		KNOWN EXTENT OF DISEASE [select all that apply]				
Histology / Pathology		No evidence of disease Site				
Please select one of the following:		Primary lesion	Primary lesion Site			
New diagnosis / Initial staging		Local recurrence Site				
Restaging / Surveillance		Loco-regional involvement Site				
Assess RX response		Systemic disease Site				
Previous malignancies		Equivocal Site				
Clinical details						
RECENT TREATMENT DETAILS			RECENT RELEVANT IMAGING			
Surgery: Site	Da	te	CT Date	Provider		
Radiotherapy Chen	notherapy	Combined	MRI Date	Provider		
Date of last Radio/Chemo to	reatment		PET Date	Provider		
Date of next Radio/Chemo	treatment		Other Date	Provider		
WHAT WOULD YOUR MA	NAGEMENT I	PLAN BE IF PET WERE U	JNAVAILABLE?			
Intention of plan: Cu	ırative or	Palliative				
Surgery		Radiotherapy		Chemoradiation alone		
Chemoradiation then	surgery	Chemotherap	y alone	alone Chemotherapy then surgery		
Biopsy		Observation o	only	Other		
DHB APPROVED IN	DICATION	NS - MUST BE COMPL	ETED FOR ALL DHE	FUNDED CASES		
COLORECTAL	CR1	HEAD & NECK	HN1	SARCOMA	SA1	
COLORECTAL	CR1 CR2 CR3	HEAD & NECK	☐ HN1 ☐ HN2 ☐ HN3		SA1	
COLORECTAL [CR2	HEAD & NECK OESOPHAGUS	HN2			
	CR2 CR3		HN2 HN3 OE1	NEUROENDOCRINE	SA2	
	CR2 CR3 AN1 AN2	OESOPHAGUS	HN2 HN3	NEUROENDOCRINE TUMOUR THYROID	SA2 NE1 TH1	
ANAL [CR2 CR3 AN1 AN2	OESOPHAGUS	☐ HN2 ☐ HN3 ☐ OE1 ☐ SK1	NEUROENDOCRINE TUMOUR	SA2	
ANAL [CR2 CR3 AN1 AN2 LU1 LU2	OESOPHAGUS SKIN	HN2 HN3 OE1 SK1 SK2	NEUROENDOCRINE TUMOUR THYROID	SA2 NE1 TH1 GL1	
ANAL [CR2 CR3 AN1 AN2 LU1 LU2 LU3 LY1 LY2	OESOPHAGUS SKIN	HN2 HN3 OE1 SK1 SK2 GY1	NEUROENDOCRINE TUMOUR THYROID GLIOMA	SA2 NE1 TH1 GL1 GL2	
ANAL [CR2 CR3 AN1 AN2 LU1 LU2 LU3 LY1 LY2 LY3	OESOPHAGUS SKIN CERVICAL	HN2 HN3 OE1 SK1 SK2 GY1 GY2	NEUROENDOCRINE TUMOUR THYROID GLIOMA	SA2 NE1 TH1 GL1 GL2 HB1	
ANAL [CR2 CR3 AN1 AN2 LU1 LU2 LU3 LY1 LY2	OESOPHAGUS SKIN CERVICAL OVARIAN	HN2 HN3 OE1 SK1 SK2 GY1 GY2 GY3	NEUROENDOCRINE TUMOUR THYROID GLIOMA HEPATOBILIARY	SA2 NE1 TH1 GL1 GL2 HB1 HB2	
ANAL [LUNG [LYMPHOMA	CR2 CR3 AN1 AN2 LU1 LU2 LU3 LY1 LY2 LY3 LY4 LY5	OESOPHAGUS SKIN CERVICAL OVARIAN EPILEPSY GIST	☐ HN2 ☐ HN3 ☐ OE1 ☐ SK1 ☐ SK2 ☐ GY1 ☐ GY2 ☐ GY3 ☐ EP1 ☐ GT1	NEUROENDOCRINE TUMOUR THYROID GLIOMA HEPATOBILIARY GRAFT INFECTION	SA2 NE1 TH1 GL1 GL2 HB1 HB2 GR1 TE1	
ANAL LUNG LYMPHOMA OTHER: If the condition if forward your request and	CR2 CR3 AN1 AN2 LU1 LU2 LU3 LY1 LY2 LY3 LY4 LY5 s outside the	OESOPHAGUS SKIN CERVICAL OVARIAN EPILEPSY GIST above criteria it will ne information to the relev	HN2 HN3 OE1 SK1 SK2 GY1 GY2 GY3 GY3 DEP1 GT1 ed to be approved by	NEUROENDOCRINE TUMOUR THYROID GLIOMA HEPATOBILIARY GRAFT INFECTION TESTICULAR y the PET Variance Commit	SA2 NE1 TH1 GL1 GL2 HB1 HB2 GR1 TE1	
ANAL LUNG LYMPHOMA OTHER: If the condition i	CR2 CR3 AN1 AN2 LU1 LU2 LU3 LY1 LY2 LY3 LY4 LY5 s outside the	OESOPHAGUS SKIN CERVICAL OVARIAN EPILEPSY GIST above criteria it will ne information to the relev	HN2 HN3 OE1 SK1 SK2 GY1 GY2 GY3 GY3 DEP1 GT1 ed to be approved by	NEUROENDOCRINE TUMOUR THYROID GLIOMA HEPATOBILIARY GRAFT INFECTION TESTICULAR y the PET Variance Commit	SA2 NE1 TH1 GL1 GL2 HB1 HB2 GR1 TE1	
ANAL LUNG LYMPHOMA OTHER: If the condition if forward your request and	CR2 CR3 AN1 AN2 LU1 LU2 LU3 LY1 LY2 LY3 LY4 LY5 s outside the	OESOPHAGUS SKIN CERVICAL OVARIAN EPILEPSY GIST above criteria it will ne information to the relev	HN2 HN3 OE1 SK1 SK2 GY1 GY2 GY3 GY3 DEP1 GT1 ed to be approved by	NEUROENDOCRINE TUMOUR THYROID GLIOMA HEPATOBILIARY GRAFT INFECTION TESTICULAR y the PET Variance Commit	SA2 NE1 TH1 GL1 GL2 HB1 HB2 GR1 TE1	
ANAL LUNG LYMPHOMA OTHER: If the condition if forward your request and	CR2 CR3 AN1 AN2 LU1 LU2 LU3 LY1 LY2 LY3 LY4 LY5 s outside the l supporting occdhb.org.n	OESOPHAGUS SKIN CERVICAL OVARIAN EPILEPSY GIST above criteria it will ne information to the releving the second secon	HN2 HN3 OE1 SK1 SK2 GY1 GY2 GY3 GY3 DEP1 GT1 ed to be approved by	NEUROENDOCRINE TUMOUR THYROID GLIOMA HEPATOBILIARY GRAFT INFECTION TESTICULAR y the PET Variance Commit ce Committee.	SA2 NE1 TH1 GL1 GL2 HB1 HB2 GR1 TE1	
ANAL LUNG LYMPHOMA OTHER: If the condition i forward your request and Email: RES-Petscanning @	CR2 CR3 AN1 AN2 LU1 LU2 LU3 LY1 LY2 LY3 LY4 LY5 s outside the l supporting occdhb.org.n	OESOPHAGUS SKIN CERVICAL OVARIAN EPILEPSY GIST above criteria it will ne information to the releving the second secon	HN2 HN3 OE1 SK1 SK2 GY1 GY2 GY3 FP1 GT1 ed to be approved by vant PET Scan Varian	NEUROENDOCRINE TUMOUR THYROID GLIOMA HEPATOBILIARY GRAFT INFECTION TESTICULAR y the PET Variance Commit ce Committee.	SA2 NE1 TH1 GL1 GL2 HB1 HB2 GR1 TE1	
ANAL LUNG LYMPHOMA OTHER: If the condition i forward your request and Email: RES-Petscanning @	CR2 CR3 AN1 AN2 LU1 LU2 LU3 LY1 LY2 LY3 LY4 LY5 s outside the l supporting occdhb.org.n	OESOPHAGUS SKIN CERVICAL OVARIAN EPILEPSY GIST above criteria it will ne information to the relevente to	HN2 HN3 OE1 SK1 SK2 GY1 GY2 GY3 FP1 GT1 ed to be approved by vant PET Scan Varian	NEUROENDOCRINE TUMOUR THYROID GLIOMA HEPATOBILIARY GRAFT INFECTION TESTICULAR y the PET Variance Commit ce Committee.	SA2 NE1 TH1 GL1 GL2 HB1 HB2 GR1 TE1 tee. Please	
ANAL LUNG LYMPHOMA OTHER: If the condition i forward your request and Email: RES-Petscanning@ PET Variance Committee A	CR2 CR3 AN1 AN2 LU1 LU2 LU3 LY1 LY2 LY3 LY4 LY5 s outside the l supporting occdhb.org.n	OESOPHAGUS SKIN CERVICAL OVARIAN EPILEPSY GIST above criteria it will ne information to the relevente to	HN2 HN3 OE1 SK1 SK2 GY1 GY2 GY3 FP1 GT1 ed to be approved by vant PET Scan Varian	NEUROENDOCRINE TUMOUR THYROID GLIOMA HEPATOBILIARY GRAFT INFECTION TESTICULAR y the PET Variance Commit ce Committee.	SA2 NE1 TH1 GL1 GL2 HB1 HB2 GR1 TE1	

Hours Weekdays 8am - 4.30pm

www.pacificradiology.com

 \leftarrow JOHNSONVILLE KARORI \rightarrow